How much funding has Allele Biotechnology raised?

Allele Biotechnology has raised $43.8M in total funding. Key investors include Yuan Capital, ARPA-H, NIH, CIRM.

Who is the CEO of Allele Biotechnology?

Jiwu Wang, PhD is the CEO of Allele Biotechnology. The company was founded in 1999.

Where is Allele Biotechnology located?

Allele Biotechnology is headquartered in San Diego, USA.

What funding stage is Allele Biotechnology at?

Allele Biotechnology is currently at the Active stage.

How many employees does Allele Biotechnology have?

Allele Biotechnology has approximately 11-50 employees.

Allele Biotechnology

Name: AM Companies Database
Creator: AMPulse
License: https://creativecommons.org/licenses/by/4.0/

PlatformSan Diego, USAFounded 1999· One of 203 Platform companies tracked by AMPulse

A clinical-stage biotechnology company developing mRNA-based cellular reprogramming technologies and 3D-bioprinted human organs for regenerative medicine.

CEO / Founder: Jiwu Wang, PhD
Team Size: 11-50
Stage: Active
Total Funding: $43.8M
Latest Round: Grant
Key Investors: Yuan Capital, ARPA-H, NIH, CIRM

Technology & Products

Key Products

Proprietary 'footprint-free' mRNA-based cellular reprogramming technology; high-resolution 3D bioprinting; in-house cGMP manufacturing; iPSC-based cell therapy platform; development of iPSC-derived cell therapies for diabetes and spinal cord injury; mNeonGreen fluorescent protein; 3D bioprinted human organs (e.g., livers).

Technological Advantage

Operates the world's first cGMP-compliant facility dedicated to mRNA-based iPSC production, combining proprietary high-resolution 3D bioprinting with advanced stem cell biology to create vascularized, functional organoids.

Differentiation

Value Proposition

Provides a safer, 'footprint-free' mRNA reprogramming method to create high-quality induced pluripotent stem cells (iPSCs) and functional 3D-printed tissues, bypassing the risks of genomic integration and donor organ shortages.

How They Differentiate

Proprietary 'footprint-free' mRNA-based cellular reprogramming that avoids viral or DNA integration, combined with high-resolution 3D bioprinting and in-house cGMP manufacturing.

Market & Competition

Target Customers

Pharmaceutical and biotech companies, academic research institutions, and eventually healthcare systems/surgeons requiring transplantable tissues.

Industry Verticals

["Regenerative Medicine","Biopharmaceutical Research","Drug Discovery & Toxicity Testing","Cell and Gene Therapy"]

Competitors

Allele Life Sciences, Abbiotec, Zymo Research

Growth & Milestones

Growth Metrics

Transitioned from a reagent supplier to a clinical-stage platform company; secured major federal funding for organ transplant trials.

Major Milestones

["Founded in 1999 as a molecular biology reagent provider.","Patented breakthrough mRNA-based iPSC reprogramming technology in 2011.","Established the world's first cGMP-compliant facility dedicated to mRNA-iPSC production.","Awarded a $25.8M ARPA-H grant in 2025 for the 'LIVER-PRINT' project to develop 3D-printed liver transplants."]

Notable Customers

University of California San Diego (UCSD); Cellular Logistics

https://www.allelebiotech.com

Why this company matters

Allele Biotechnology occupies a unique position at the intersection of cellular reprogramming and additive manufacturing. While most bioprinting companies rely on immortalized cell lines or viral vectors, Allele uses mRNA to generate induced pluripotent stem cells (iPSCs) that contain no foreign genetic material. This footprint-free approach reduces the risk of genomic integration, a critical safety advantage for therapies destined for human transplantation.

The company's core technology stack pairs its proprietary mRNA-based reprogramming method with high-resolution material extrusion (MEX) bioprinting. Allele operates what it describes as the first cGMP-compliant facility dedicated to mRNA-iPSC production, enabling it to manufacture vascularized organoids such as 3D-printed liver constructs. Its pipeline includes iPSC-derived cell therapies for diabetes and spinal cord injury, and the company also supplies the mNeonGreen fluorescent protein to the research community.

Allele serves pharmaceutical and biotech companies, academic labs, and, eventually, healthcare systems requiring transplantable tissues. Notable collaborators include the University of California San Diego, with which it is developing 3D-printed livers, and the Scintillon Institute for research on artificial organelles. In 2025, Allele received a $25.8 million ARPA-H grant for the LIVER-PRINT project, a federal push toward bioprinted organ transplants.

The company's competitive moat rests on its integrated platform: mRNA reprogramming, high-resolution bioprinting, and in-house cGMP manufacturing. Competitors such as Allele Life Sciences, Abbiotec, and Zymo Research lack this combined capability. A key open question is whether Allele can scale its organoid production from preclinical organoids to full-size, vascularized organs suitable for human transplant trials.